Journal Information
Vol. 28. Issue 7.
Pages 360-364 (October 1992)
Share
Share
Download PDF
More article options
Vol. 28. Issue 7.
Pages 360-364 (October 1992)
Full text access
La clasificación TNM del carcinoma broncogénico. Seis años después
TNM classification of bronchogenic carcinoma, 6 years after
Visits
4022
A. López-Encuentra
Servicio de Neumología. Universidad Complutense. Hospital 12 de Octubre. Madrid
This item has received
Article information

La clasificación internacional de extensión anatómica del carcinoma broncogénico (CB) de 1986, permanece totalmente vigente, habiendo sido aceptada en la práctica por todos los grupos interesados. Algunos apartados de esta clasificación (tumor del sulcus superior, adenopatías mediastínicas, T3N2) posiblemente precisen, en el futuro, de modificaciones clasificatorias.

Es imprescindible mencionar explícitamente en qué momento del estudio del paciente ha sido efectuada la clasificación. Si ha sido con los datos disponibles antes de la toracotomía (clasificación clínica) se debe nominar TNM-estadiosc; con los obtenidos macroscópicamente en la toracotomía, TNMq; con los hallazgos microscópicos con las muestras extraidas en toracotomía, TNMq-p.

Dada la existencia de numerosos métodos de estudio para la clasificación de la extensión anatómica, es conveniente señalar cuales han sido utilizados y qué criterios se han seguido para la calificación TNM-estadios, especialmente para la clasificación T3-T4c y N1-N2c. En el CB será necesario considerar una clasificación multifactorial conjunta, útil para predecir pronósticos más ajustados, ampliando la clasificación anatómica de extensión tumoral (TNM-estadios) a variables clínicas, biológicas o celulares-moleculares.

The international classification of anatomical extension of bronchogenic carcinoma dated on 1986, remains valid and has been accepted by all interested groups. However, some of its sections (tumor of sulcus superior, mediastinal adenopathies, T3N2) would require further modifications, specially in aspects related to classification. It is fundamental to mention at which moment of patient's study is the classification made. If the classification has been based on data available before thoracotomy (clinical classification) it should be called TNMstages-c, if was based on macroscopic observation during thoracotomy should be called TNM-q, and if microscopic data of samples obtained during thoracotomy were considered, then, the term TNM-c-q should be used. In view of the existence of a large number of methods available for classifying anatomical extension, the selected method used to qualify TNM-stages, specially T3-T4c and N1-N2c, should be clearly described. In the case of bronchogenic carcinoma a whole multifactorial classification leading to more accurate prognostic predictions should be envisaged. This should include not only classification of the anatomical extension, but also the consideration of some clinical, biological, and cellular variables.

Full text is only aviable in PDF
Bibliografía
[1.]
C.F. Mountain.
A new international staging system for lung cancer.
Chest, 89 (1986), pp. 225S-233S
[2.]
Grupo de Trabajo de la SEPAR para la Normativa sobre Nomenclatura y Clasificación del Carcinoma Broncogénico.
SEPAR.
Ediciones Doyma SA, (1986),
[3.]
C.F. Mountain.
Staging of lung cancer: The new international system.
Lung Cancer, 3 (1987), pp. 4-11
[4.]
C.F. Mountain.
The new international stage system for lung cancer.
Surg Clin North Am, 67 (1987), pp. 925-935
[5.]
C.F. Mountain.
New international staging of lung cancer.
Arch Bronconeumol, 23 (1987), pp. 298-305
[6.]
T. Naruke, G. Tomoyuki, R. Tsuchiya, K. Suemasu.
Prognosis and survival in resected lung carcinoma based on the new international staging system.
J Thorac Cardiovasc Surg, 96 (1988), pp. 440-447
[7.]
S. Plaja, V. Puccia, A. Russo.
Carcinoma of the lung, stage III: Experience with the new TNM-AJCC classification.
Scan J Thorac Cardiovasc Surg, 22 (1988), pp. 139-145
[8.]
L.H. Sobin, P. Hermanek, R.V. Hutter.
TNM classification of malignant tumors: A comparison between the new (1987) and the old editions.
Cancer, 61 (1988), pp. 2310-2314
[9.]
C.F. Mountain, S.D. Greenberg, A.E. Fraire.
Tumor stage in nonsmall cell carcinoma of the lung.
Chest, 99 (1991), pp. 1258-1260
[10.]
López Encuentra A. Clasificación anatómica del tumor y clasificación clínica del paciente. Decisiones individualizadas en situación clínica desfavorable. En Abordaje multidisciplinario del tratamiento del cáncer de pulmón. Ponencia I Congreso Luso-Español de Neumología. Lisboa, Mayo 1989.
[11.]
N. Roeslin, G. Chalkiadakis, P. Dumont, J.P. Witz.
A better prognostic value from a modification of lung cancer staging.
J Thorac Cardiovasc Surg, 94 (1987), pp. 504-509
[12.]
American Joint Committee on Cancer.
Staging of lung cancer.
en Manual for staging of cancer, Third edition, Lippincott JB, (1988),
[13.]
C.F. Mountain.
The value of the new TNM system.
Lung Cancer, 4 (1988), pp. P39
[14.]
A. López Encuentra.
Carcinoma broncogénico.
Diagramas de Neumología.,
[15.]
F. Sánchez Hernández, L. Hernández Blasco, R. Roca Serrano, M. Jiménez, A. López Encuentra, J. Toledo.
Análisis de la eficacia de la clasificación tumoral anatómica pretoracotomía en el carcinoma broncogénico. Comparación con la clasificación postoracotomía..
Arch Bronconeumol, 25 (1989), pp. 53
[16.]
J. Estapé, M.C. Guzman, A. Agusti.
Estudio comparativo del TNM clínico y del posquirúrgico en cáncer de pulmón no de células pequeñas. A propósito de 952 casos.
Neoplasia, 6 (1989), pp. 211-214
[17.]
H.C. Fernando, P. Goldstraw.
The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging.
Cancer, 65 (1990), pp. 2503-2506
[18.]
J.D. Cox.
The respective roles of radiation therapy and chemotherapy in non-small cell carcinoma of the lung with mediastinal but not distant metastases (N2M0).
Lung Cancer, 7 (1991), pp. 65-69
[19.]
A.G. Little, F.P. Stitik.
Clinical staging of patients with nonsmall cell lung cancer.
Chest, 97 (1990), pp. 1431-1438
[20.]
H.M. Sandler, W.J. Curran, A.T. Turrisi.
The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer.
Int J Radiat Oncol Biol Phys, 19 (1990), pp. 9-13
[21.]
B. Campling, I. Quirt, G. DeBoer, R. Feld, F.A. Shepherd, W.K. Evans.
Is bone marrow examination in small-cell lung cancer really necessary?.
Ann Intern Med, 105 (1986), pp. 508-512
[22.]
D.B. Tritz, D.C. Doll, Q.S. Ringerberg, et al.
Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables..
Cancer, 63 (1989), pp. 363-366
[23.]
C. Manegold, B. Krempien, H. Bulzebruck, P. Drigs.
Value of bilateral iliac crest needle biopsy for pretherapeutic tumor staging of bronchogenic carcinoma.
Oncology, 46 (1989), pp. 226-229
[24.]
J.W. Lewis, J.L. Peareberg, G.H. Beute, et al.
Can computed tomography of the chest stage lung cancer?. Yes and not.
Ann Thorac Surg, 49 (1990), pp. 591-595
[25.]
W.B. Gefter.
Magnetic resonance imaging in the evaluation of lung cancer.
Semin Roentgenol, 25 (1990), pp. 73-84
[26.]
J.L. Martín de Nicolás Serrahima, A. Sánchez Nistal.
Correlación tomografía computadorizada y mediastinoscopia en la extensión ganglionar del carcinoma broncogénico.
Arch Bronconeumol, 25 (1989), pp. 52
[27.]
J.B. Putnam, D.E. Lammermeier, R. Colon, M.J. McMurtrey, M.K. Ali, J.A. Roth.
Predicted pulmonary function and survival after pneumonectomy for primary lung carcinoma.
Ann Thorac Surg, 49 (1990), pp. 909-915
[28.]
C.F. Mountain.
Prognostic implications of the International Staging System for Lung Cancer.
Sem Oncol, 15 (1988), pp. 236-245
[29.]
G.B. Ratto, C. Frolar, A. Sacco, G. Motta.
The prognostic significance of minor pleural effusions in patients with potentially operable bronchogenic carcinoma.
Lung Cancer, 3 (1987), pp. 117-122
[30.]
A. Cantó, M. Martorell, A. Arnau, et al.
Significado del cáncer broncopulmonar que se acompaña de un derrame pleural homolateral.
Arch Bronconeumol, 27 (1991), pp. 254-258
[31.]
C.F. Mountain, J.M. Lukeman, S.P. Hammar, et al.
Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trial population.
J Surg Oncol, 35 (1987), pp. 147-156
[32.]
M. Vinocour, J.D. Minna.
Cellular and molecular biology of lung cancer.
Thoracic Oncology, pp. 38-50
[33.]
A.R. Feinstein, C.K. Wells.
A clinical-severity staging system for patients with lung cancer.
Medicine, 69 (1990), pp. 1-33
[34.]
P.V. Zimmerman, G.A. Hawson, M.H. Bint, P.G. Parsons.
Ploidy as a prognostic determinant in surgically treated lung cancer.
Lancet, 2 (1987), pp. 530-533
[35.]
K. Nakahara, Y. Monden, K. Ohno, et al.
Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer.
J Surg Oncol, 36 (1987), pp. 155-160
[36.]
P.C. Van-Bodegom, J.P. Baak, C. Stroet-van-Galen, et al.
The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage I resected squamous lung cancer and long-term follow-up.
Cancer, 63 (1989), pp. 143-147
[37.]
C. Hajj, R. Akoum, E. Bradley, F. Paquin, J. Ayoub.
DNA alterations al proto-oncogene loci and their clinical significance in operable non-small cell lung cancer.
Cancer, 66 (1990), pp. 733-739
Copyright © 1992. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?